
Why Reviewing Labs and Adverse Events in Isolation Is a Safety Risk
Labs and adverse events (AEs) are two views of the same patient. When medical monitors, safety reviewers, or CRAs assess them through separate workflows —
Exciting News! Saama Wins “AI-based Life Sciences Solution of the Year” Award in 2026 AI Breakthrough Awards
A Saama company that offers data analytics solutions and services for banking and capital markets, consumer goods, insurance, the public sector, and more.

Labs and adverse events (AEs) are two views of the same patient. When medical monitors, safety reviewers, or CRAs assess them through separate workflows —

Every few months, a new vendor promises a “zero touch” clinical coding automation pipeline: feed in raw text, let the algorithm match it against MedDRA

For 60 years, clinical trial data has moved on a one-way delay: sites collect it, sponsors analyze it, and only then does it reach the

There’s a quiet assumption baked into most “AI for clinical programming” pitches: that the hard part is generating code. Well, it isn’t. Any model can

Clinical development has always been expensive. But in 2026, the economics are drawing sharper attention. Developing a single new molecular entity now routinely requires between

Modern clinical trials generate data continuously, from the moment the first patient is enrolled. Yet most data management teams are still built around workflows designed

The drug development industry is moving faster than ever, and timelines are continuing to shorten across parts of the process. AI is increasingly being applied

Ask any clinical operations leader where study startup time disappears, and the answer rarely points to a single dramatic failure. More often, the culprit is

Clinical trials generate enormous amounts of data. For decades, the industry has relied on a familiar approach to keep that data clean through rules, edit
Get our perspectives on AL/ML in the life sciences industry directly to your inbox.